Novavax, Inc. (NVAX): Price and Financial Metrics

Novavax, Inc. (NVAX)

Today's Latest Price: $126.25 USD

2.91 (-2.25%)

Updated Dec 4 4:00pm

Add NVAX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

NVAX Stock Summary

  • Price to trailing twelve month operating cash flow for NVAX is currently 128.25, higher than 96.51% of US stocks with positive operating cash flow.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 29.36 for Novavax Inc; that's greater than it is for 98.77% of US stocks.
  • Revenue growth over the past 12 months for Novavax Inc comes in at 1,181.88%, a number that bests 99.33% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to NVAX, based on their financial statements, market capitalization, and price volatility, are DRNA, CTMX, NKTR, AGIO, and RARE.
  • Visit NVAX's SEC page to see the company's official filings. To visit the company's web site, go to

NVAX Stock Price Chart Interactive Chart >

Price chart for NVAX

NVAX Price/Volume Stats

Current price $126.25 52-week high $189.40
Prev. close $129.16 52-week low $3.65
Day low $125.04 Volume 2,181,700
Day high $130.49 Avg. volume 7,504,021
50-day MA $100.95 Dividend yield N/A
200-day MA $75.56 Market Cap 8.04B

Novavax, Inc. (NVAX) Company Bio

Novavax, Inc. focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company was founded in 1987 and is based in Gaithersburg, Maryland.

NVAX Latest News Stream

Event/Time News Detail
Loading, please wait...

NVAX Latest Social Stream

Loading social stream, please wait...

View Full NVAX Social Stream

Latest NVAX News From Around the Web

Below are the latest news stories about Novavax Inc that investors may wish to consider to help them evaluate NVAX as an investment opportunity.

The Real Value in Novavax Goes Beyond the Coronavirus

NVAX stock is up over 2,000% on hopes it will deliver a vaccine for the novel coronavirus. However, the real value comes from its flu vaccine.

InvestorPlace | October 2, 2020

Will October Be A Reachable Goal For A Vaccine?

Despite slim chances that the COVID-19 vaccine will see the light of the public day in October, Pfizer Inc. (NYSE: PFE ) is getting our hopes up. According to SVB Leerink, a Wall Street firm, even though Moderna Inc (NASDAQ: MRNA ) and Pfizer began their trials on the same day, Pfizer's is built for speed. As a reminder, there are four vaccines undergoing the final stage of U.S. clinical trials and a fifth by Maryland-based Novavax, Inc. (NASDAQ: NVAX ) on the way. Although the final stage of clinical trials in the U. S. will begin in October Phase 3 in the UK is well underway as of September 25 th . The four other candidates besides Moderna and Pfizer are Johnson & Johnson (NYSE: JNJ ) and AstraZeneca plc (NYSE: AZN ). But unlike Johnson & Johnson and AstraZeneca which have said they w...

Benzinga | October 1, 2020

JSS academy in Mysuru to carry out clinical trials for Novavax vaccine

JSS Academy of Higher Education and Research (JSSAHER), which has already begun phase three of the clinical trials for vaccine candidate Covishield at its facility in Mysuru, has been approached for h

The Hindu | October 1, 2020

Vaccine Market Professional Survey Report: Merck Co., Inc, Sanofi, CSL Limited, Panacea Biotec Ltd., Novavax, Emergent BioSolutions Inc, Inovio Pharmaceuticals, Inc

Vaccine Market By Technology (Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Others), Type (Monovalent Vaccines, Multivalent Vaccines), Indication (Pneumococcal Disease, Influenza, Meningococcal Disease, Polio, Rotavirus, Hepatitis, Dengue, Herpes Zoster, Others), Route of Administration (Oral, Parenteral), By End Users (Hospitals,

OpenPR | September 30, 2020

COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 Featuring Major Players - Pfizer, GSK, Inovio Pharma, J&J, Novavax, Heat Biologics, Sanofi, BioNTech, Vaxart, and Vir Biotechnology -

DUBLIN--(BUSINESS WIRE)--The "COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020" report has been added to's offering. COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 provides the strategists, marketers and senior management with the critical information they need to assess the global COVID-19 vaccine & therapeutics clinical trial analysis 2020 market. Major players in the COVID-19 vaccine and therapeutics clinical trial analysis market

Business Wire | September 30, 2020

Read More 'NVAX' Stories Here

NVAX Price Returns

1-mo 35.59%
3-mo 35.85%
6-mo 181.87%
1-year 2,802.30%
3-year 344.54%
5-year -21.78%
YTD 3,072.11%
2019 -89.18%
2018 48.39%
2017 -1.59%
2016 -84.98%
2015 41.48%

Continue Researching NVAX

Want to see what other sources are saying about Novavax Inc's financials and stock price? Try the links below:

Novavax Inc (NVAX) Stock Price | Nasdaq
Novavax Inc (NVAX) Stock Quote, History and News - Yahoo Finance
Novavax Inc (NVAX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7448 seconds.